戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mast cell stabilizer' disodium cromoglycate (cromolyn).
2 acid), and potent anti-Alzheimer compound (F-cromolyn).
3 EIA for up to 3 h and is more effective than cromolyn.
4 e are treated with the mast cell stabilizer, cromolyn.
5 out preincubation with luteolin, methlut, or cromolyn (1-100 mumol/L) for 2 or 24 hours, after which
6 nhaled 4 ml of either heparin (20,000 u/ml), cromolyn (20 mg), or placebo solutions with increasing p
7 ded albuterol (81%), inhaled steroids (38%), cromolyn (35%), and theophylline (23%).
8                              Here we utilize cromolyn, a mast cell inhibitor with anti-inflammatory c
9                                              Cromolyn, a mast cell stabilizer, injected centrally 1 h
10                                              Cromolyn, a mast cell stabilizer, reduced BALF cells and
11   Prevention of mast cell degranulation with cromolyn, ablation of visceral afferents with capsaicin,
12                                              Cromolyn and a new fluorinated analog dramatically reduc
13                                 Furthermore, cromolyn and F-cromolyn augment neurite outgrowth in PC1
14                   Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins
15 microglia more readily phagocytose AB42 with cromolyn and F-cromolyn relative to controls.
16                    Subsequent treatment with cromolyn and F-cromolyn resulted in reduced secretion of
17 ugs such as mast cell stabilizers (including cromolyn and the H1-antihistamine ketotifen), suplatast
18       Other anti-inflammatory agents such as cromolyn and the new class of leukotriene receptor antag
19 n-13 therapy, anti-IgE therapy, montelukast, cromolyn, and anti-TNF therapy.
20 ndition became resistant to corticosteroids, cromolyn, and intravenous gamma globulin.
21 ough heparin offered greater protection than cromolyn (at 1 to 3 h), both agents were ineffective whe
22  1 h and 3 h, respectively, before exercise; cromolyn attenuated the responses by 37%, 46%, and 41%,
23                  Furthermore, cromolyn and F-cromolyn augment neurite outgrowth in PC12 neuronal cell
24 LIGRL-NH(2); this effect was not observed in cromolyn-, capsaicin-, or RP67580-treated rats but was d
25    Inhaled steroids and, to a lesser extent, cromolyn confer significant protection against exacerbat
26 y of the antiasthma and antiallergic ligands cromolyn disodium and nedocromil sodium, we identified t
27  is a more potent inhibitor than luteolin or cromolyn for beta-hexosaminidase and histamine secretion
28                                  Heparin and cromolyn had no effect on baseline SGaw but attenuated t
29 rt by 40% to 85%, whereas prostaglandins and cromolyn had no effect.
30  To better understand the mechanistic effect cromolyn has in slowing down or halting the neuroinflamm
31                                              Cromolyn, in a new redesigned dry powder formulation, is
32                                              Cromolyn is a known mast cell stabilizer and is approved
33                                    Moreover, cromolyn-mediated pharmacologic blockade of mast cells a
34          However, neither the treatment with cromolyn nor the deficiency of mast cells (WBB6F1-Kit(W/
35                         The direct effect of cromolyn on HMC3 microglia is on cytokines and chemokine
36                 Mast cell stabilization with cromolyn or lodoxamide markedly reduced active renin ove
37 that interfere with histamine (pyrilamine or cromolyn), or a neurokinin antagonist (spantide).
38          Although the effects of pyrilamine, cromolyn, or aprepitant on ET-induced vascular leakage s
39 results bolster our understanding of how our cromolyn platform modulates toxic microglia behavior as
40                               We propose the cromolyn platform targets multiple proteins upstream of
41    Additionally, we show that cromolyn and F-cromolyn reduce pro-inflammatory proteins PLP1, PELP1, H
42                     The mast cell stabilizer cromolyn reduced the second contraction (E(max), 27% +/-
43 readily phagocytose AB42 with cromolyn and F-cromolyn relative to controls.
44     Subsequent treatment with cromolyn and F-cromolyn resulted in reduced secretion of collagen XVIII
45                     Here we demonstrate that cromolyn sodium (disodium cromoglycate), a Food and Drug
46                               Treatment with cromolyn sodium decreased biliary proliferation, fibrosi
47                                              Cromolyn sodium effectively stabilized mast cells, yet i
48 knockout mice (9-11 weeks) were treated with cromolyn sodium for 1 week to block MC-derived histamine
49 d mice treated with the MC stabilizing agent cromolyn sodium had dramatically reduced Th2 priming and
50   Pretreatment with the mast cell stabilizer cromolyn sodium improved analgesia following low doses o
51 ation of the potential long-term efficacy of cromolyn sodium in Alzheimer disease.
52 were reduced following MC stabilization with cromolyn sodium in Mdr2(-/-) mice.
53 oprotective and anti-inflammatory effects of cromolyn sodium in the SOD1(G93A) mouse model of ALS.
54        Together, these findings suggest that cromolyn sodium provides neuroprotection in the SOD1(G93
55                    Our results indicate that cromolyn sodium treatment significantly delayed the onse
56                                 Furthermore, cromolyn sodium treatment was associated with reduced in
57       In a phase 2A study, inhaled RVT-1601 (cromolyn sodium) reduced daytime cough and 24-hour avera
58 f inhaled heparin in EIA and compare it with cromolyn sodium, a mast cell stabilizing agent with esta
59 tudies from our group have demonstrated that cromolyn sodium, an FDA approved compound, exerts neurop
60 ns have been used including corticosteroids, cromolyn sodium, and leukotriene inhibitors.
61 ls pretreated with the mast cell stabilizer, cromolyn sodium, mast cell degranulation was blocked, an
62                         In mice treated with cromolyn sodium, MC infiltration and tumor growth decrea
63 amine, histidine decarboxylase inhibitor, or cromolyn sodium.
64 ) markers were measured in mice treated with cromolyn sodium.
65 week of daily intraperitoneally administered cromolyn sodium.
66 mpared H1 - and H2 -antihistamines with oral cromolyn sodium.
67 pression that decreased with pretreatment of cromolyn sodium.
68 olone acetonide at the ulcer margin; topical cromolyn sodium; oral dapsone, prednisone, cyclosporine,
69 with AD progression, we tested the effect of cromolyn to dampen the inflammatory response in the huma
70 capabilities, and its fluorinated analogue F-cromolyn to study fibrosis-related protein regulation an
71  junction of the tibialis anterior muscle in cromolyn treated transgenic SOD1(G93A) mice.
72                                      Lastly, cromolyn treatment decreased the expression of pro-infla
73  activity (P<0.05), after 8 weeks of topical cromolyn treatment.
74                                              Cromolyn was similarly associated with reduced risk, esp
75 lyp/lyp rats with the mast cell "stabilizer" cromolyn, which significantly (p < 0.05) delayed T1DM on
76 osed to beta agonists or xanthines (0.8%) or cromolyn without steroids (0.1%).
77 ormal birthweight and full-term infants, the cromolyn without steroids group had the greatest decline